Senior Financial Analyst Corporate Finance (M&A and BD)
Exelixis
Summary
The Senior Financial Analyst - BD and M&A will be responsible for the execution of financial analysis to support the executive leadership team on critical business decisions. This role will perform duties to support corporate development, business development, strategic planning, life cycle management and general corporate finance activities.
Job description
Essential Duties/Responsibilities
Corporate and Business Development
- Prepare company/asset valuation analyses on potential licensing and M&A transactions
- Build merger consequences models to evaluate potential acquisitions
- Evaluate in-licensing opportunities from a financial/business perspective
- Test sensitivity of deal economics to variances in key assumptions, including synergies
- Contribute to preparation and presentation of deal summaries and recommendations to senior management
Lifecycle Management and Strategic Planning
- Build and update long-range planning models and assist in preparation of BoD presentations
- Perform discounted cash flow analyses to support lifecycle management of pipeline assets
- Perform company-level and project-level valuation analysis
- Perform specific value-added analyses, e.g., resource allocation, profitability analysis, sensitivity/scenario analyses, benchmarking
- Evaluate and compare the financial benefits of life cycle management initiatives/alternatives
- Build analysis to support business partner recommendations on investment/divestment decisions to executive management and Board of Directors
- Build and maintain effective relationships with cross-functional stakeholders to support collaboration, alignment, and successful execution of business priorities
Corporate Finance
- Develop and standardize financial analysis models employing best-in-class financial analysis techniques, including scenario modelling
- Assist in development of cost-effective strategies for financing the company's business initiatives and optimizing the company's capital structure
- Performs comparable company analysis on biotechnology peers in a broad number of areas including financings, capital structure, deal-making, share performance, etc.
- Create company profiles on biotech and pharma peers
- Maintain corporate weighted average cost of capital (WACC) calculation
- Proactively monitors industry news, trends, and market dynamics
- Performs other duties as assigned
- Complies with all policies and standards
Supervisory Responsibilities
No supervisory responsibilities
Education/Experience/Knowledge/Skills & Abilities
Education
- BS/BA degree in related discipline and 5 years of related experience; or
- MBA degree in related discipline and 3 year of related experience; or,
- Equivalent combination of education and experience
Experience
- Experience in investment banking/management consulting preferred
- Experience in Biotech/Pharmaceutical industry preferred
- Experience working with cross-functional teams is a plus
Knowledge, Skills and Abilities
Required:
- Strong expertise in financial modeling and financial statement analysis (GAAP and non-GAAP)
- Advanced knowledge of Excel, PowerPoint, FactSet (or comparable financial analytics tools e.g., Bloomberg, Capital IQ)
- Advanced Excel modelling
- Expertise in evaluating and modeling various funding arrangements (e.g., revolver, term loans, equity issuances, etc.)
- Strong analytical, strategic, problem solving and organizational skills
- Strong attention to detail
- Strong communication (verbal and written) and presentation skills
- Knowledgeable about the biotech / pharma industry
- Adaptability to evolving business needs, priorities, and approaches
- Ability to effectively manage multiple projects and competing priorities
- Demonstrated understanding of operational drivers of the financial analyses
- Ability to translate financial analyses into clear business implications and communicate them effectively to cross-functional teams and leadership
- Ability to navigate ambiguity and perform analyses in situations with incomplete information and evolving assumptions
Travel Requirements
0% This position does not require travel.
Requirements
- BS/BA degree in related discipline and 5 years of related experience; or MBA degree in related discipline and 3 years of related experience; or equivalent combination of education and experience
- Strong expertise in financial modeling and financial statement analysis (GAAP and non-GAAP)
- Advanced knowledge of Excel, PowerPoint, FactSet (or comparable financial analytics tools e.g., Bloomberg, Capital IQ)
- Advanced Excel modelling
- Expertise in evaluating and modeling various funding arrangements (e.g., revolver, term loans, equity issuances, etc.)
- Strong analytical, strategic, problem solving and organizational skills
- Strong attention to detail
- Strong communication (verbal and written) and presentation skills
- Knowledgeable about the biotech / pharma industry
- Adaptability to evolving business needs, priorities, and approaches
- Ability to effectively manage multiple projects and competing priorities
- Demonstrated understanding of operational drivers of the financial analyses
- Ability to translate financial analyses into clear business implications and communicate them effectively to cross-functional teams and leadership
- Ability to navigate ambiguity and perform analyses in situations with incomplete information and evolving assumptions
Benefits
- 401(k) Matching
- Medical, Dental & Vision
- Life & Disability Insurance
- Flexible Spending Accounts
- Discretionary Annual Bonus
- Company Stock Purchase
- Long-Term Incentives
- 15 Vacation Days
- 17 Paid Holidays
- Up to 10 Sick Days
Company overview
Exelixis, Inc. is an oncology-focused biotechnology company headquartered in Alameda, California, that specializes in the discovery, development, and commercialization of innovative cancer treatments. Founded in 1994, the company has evolved into a multi-platform cancer organization with a proven track record in the challenging biotech sector. Exelixis is best known for its flagship molecule cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET, which has led to several approved drugs for difficult-to-treat cancers. The company's portfolio includes four approved drugs, with two derived from cabozantinib, and it maintains a robust pipeline of next-generation cancer treatments. With approximately 1,500 employees across five continents, Exelixis operates as a publicly traded company (NASDAQ: EXEL) and has established strategic alliances with major pharmaceutical and biotechnology partners. The company's mission centers on transforming science into new treatments that give cancer patients and their families hope for the future, with every employee united in this ambitious cause.